SLC5A2 and type 2 diabetes mellitus: In the United States of America, the Food and Drug Administration (FDA) has authorised the use of four SGLT2 inhibitors including canagliflozin, dapagliflozin, empagliflozin and ertugliflozin in treating T2DM patients.